



LKT Laboratories, Inc.

**AZD-1152-HQPA**

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

## Product Information

Product ID A9714

CAS No. 722544-51-6

### Chemical Name

Synonym AZD1152-HQPA

Formula  $C_{26}H_{30}FN_7O_3$

Formula Wt. 507.56

### Melting Point

Purity  $\geq 98\%$

Solubility DMSO 102 mg/mL (200.96 mM)


Ethanol 3 mg/mL (5.91 mM)

Water Insoluble

Store Temp  $-20^{\circ}C$

Ship Temp Ambient

**Description** AZD-1152-HQPA inhibits aurora kinases B and C (AurB, AurC), preventing mitotic spindle formation and proper completion of mitosis. This compound exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for cancers with solid tumors. In acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) cells, AZD-1152-HQPA induces apoptosis, inhibiting proliferation. AZD-1152-HQPA also induces apoptosis in glioma cells, inhibiting proliferation in vitro and tumor growth in vivo.



**Bulk quantities available upon request**

Product ID	Size
A9714	1 mg
A9714	5 mg
A9714	10 mg

**References** Hartsink-Segers SA, Zwaan CM, Exalto C, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. *Leukemia*. 2013 Mar;27(3):560-8. PMID: 22940834.

Diaz RJ, Golbourn B, Shekarforoush M, et al. Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. *J Neurooncol*. 2012 Jul;108(3):349-60. PMID: 22382783.

Boss DS, Witteveen PO, van der Sar J, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. *Ann Oncol*. 2011 Feb;22(2):431-7. PMID: 20924078.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.